An update on redifferentiation strategies for radioactive iodine-refractory differentiated thyroid carcinoma
Endocrine · 04.09.2024 · 87 (1) · 1-10
DOI: 10.1007/s12020-024-04018-5 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrine, online erschienen am 04.09.2024. Verfasst von Theodora Pappa und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Boston, MA, USA. tpappa@bwh.harvard.edu. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Iodine Radioisotopes. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: NIH HHS, NIH, American Thyroid Association.
Abstract (Originalsprache)
PURPOSE: Although most patients with differentiated thyroid carcinoma (DTC) have an excellent prognosis, a subset will experience radioactive iodine refractory (RAI-R) disease, associated with recurrence, distant metastases and worse prognosis. In recent years, redifferentiation has emerged as an attractive approach for patients with RAI-R DTC, a strategy to induce iodine uptake in RAI-R DTC tumor cells and ultimately prolong time to initiation of systemic therapy. METHODS: An overview and critical appraisal of the existing literature on redifferentiation will be presented in this review under the lens of the genotype-specific targeted therapy administered with redifferentiation intent. RESULTS/CONCLUSIONS: Due to the significant heterogeneity across studies, it will be key to harmonize research methodology and support future larger, multicenter prospective trials in order to identify the most suitable candidates for this therapeutic strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Boston, MA, USA. tpappa@bwh.harvard.edu.
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. tpappa@bwh.harvard.edu.
- Mass General Brigham, Boston, MA, USA. tpappa@bwh.harvard.edu.
- Harvard Medical School, Boston, MA, USA. tpappa@bwh.harvard.edu.
- Mass General Brigham, Boston, MA, USA.
- Harvard Medical School, Boston, MA, USA.
ORCID-Profile: Theodora Pappa
Förderung
- NIH HHS
- NIH
- American Thyroid Association
- Sperling Family Fellowship
Zitieren
APA
Pappa, T., & Wirth, L. (2024). An update on redifferentiation strategies for radioactive iodine-refractory differentiated thyroid carcinoma. Endocrine, 87(1), 1-10. https://doi.org/10.1007/s12020-024-04018-5
Vancouver
Pappa T, Wirth L. An update on redifferentiation strategies for radioactive iodine-refractory differentiated thyroid carcinoma. Endocrine. 2024;87(1):1-10. doi:10.1007/s12020-024-04018-5
BibTeX
@article{Pappa2024,
author = {Pappa, Theodora and Wirth, Lori},
title = {An update on redifferentiation strategies for radioactive iodine-refractory differentiated thyroid carcinoma},
journal = {Endocrine},
year = {2024},
volume = {87},
number = {1},
pages = {1--10},
doi = {10.1007/s12020-024-04018-5}
}
EUVIMED